Drug Overview
Nimenrix (quadrivalent polysaccharide tetanus toxoid conjugate vaccine; Pfizer) is a conjugated polysaccharide vaccine indicated for active immunization to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis (N. meningitidis) serogroups A, C, Y, and W-135 in individuals from the age of six weeks. It induces the production of bactericidal antibodies against capsular polysaccharides of N. meningitidis group A, C, W-135, and Y.
Nimenrix is the only meningococcal vaccine against serotypes A, C, W-135, and Y (MenACWY) recommended for use in infants as early as six weeks of age in the EU.
Despite that, it will continue to face significant competition in the European market from Menveo (quadrivalent oligosaccharide diphtheria CRM-197 conjugate vaccine; GlaxoSmithKline), which was approved two years before Nimenrix. As national recommendations restrict the use of MenACWY vaccines to at-risk, usually adult populations, the commercial potential of Nimenrix is limited. Sales of Nimenrix will be further threatened by pipeline vaccine MenABCW-135Y (pentavalent meningococcal conjugate vaccine; GlaxoSmithKline) starting from 2022, if it manages to demonstrate non-inferior immunogenicity against all five strains when compared to marketed vaccines.
Nimenrix (quadrivalent polysaccharide tetanus toxoid conjugate vaccine; Pfizer) is a conjugated polysaccharide vaccine indicated for active immunization to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis (N. meningitidis) serogroups A, C, Y, and W-135 in individuals from the age of six weeks. It induces the production of bactericidal antibodies against capsular polysaccharides of N. meningitidis group A, C, W-135, and Y.
Nimenrix is the only meningococcal vaccine against serotypes A, C, W-135, and Y (MenACWY) recommended for use in infants as early as six weeks of age in the EU.
Despite that, it will continue to face significant competition in the European market from Menveo (quadrivalent oligosaccharide diphtheria CRM-197 conjugate vaccine; GlaxoSmithKline), which was approved two years before Nimenrix. As national recommendations restrict the use of MenACWY vaccines to at-risk, usually adult populations, the commercial potential of Nimenrix is limited. Sales of Nimenrix will be further threatened by pipeline vaccine MenABCW-135Y (pentavalent meningococcal conjugate vaccine; GlaxoSmithKline) starting from 2022, if it manages to demonstrate non-inferior immunogenicity against all five strains when compared to marketed vaccines.
Table of Contents
OVERVIEW- Drug Overview
- Product Profiles
- Nimenrix : Meningococcal vaccines
LIST OF TABLES
Table 1: Nimenrix drug profile
Table 2: Approval history of Nimenrix for meningococcal vaccination in the five major EU markets
Table 3: Late-phase trials of Nimenrix for meningococcal vaccination
Table 4: Nimenrix for meningococcal disease – SWOT analysis
